Standardized analysis of morphological OCT parameters and correlation with best-corrected visual acuity (BCVA) in antiangiogenic therapy of neovascular age-related macular degeneration (AMD)

Christian Simader, S. Waldstein, M. Kundi & U. Schmidt-Erfurth
Methods: 1240 patients were treated using ranibizumab/aflibercept in a fixed (year one) and a PRN (year two) regimen in a prospective randomized trial (VIEW2). OCT data were obtained monthly by a standardized protocol and analyzed by an independant reading center. Results: At baseline, 64%[for full text, please go to the a.m. URL]